Business Wire

Miller Barondess Files Lawsuit Against Nissan North America Over Alleged Scheme to Undermine Successful Automotive Dealer

Share

Trophy Universal City Group, LLC and Trophy West Covina Motor Group, LLC (“Trophy Group”) have filed a lawsuit against Nissan North America, Inc., accusing the automaker of orchestrating a deliberate and nefarious scheme to suffocate vehicle inventory and squeeze out the Trophy Group. The case centers on two Los Angeles County Nissan dealerships—Universal City Nissan and West Covina Nissan—led by global automotive entrepreneur and Trophy Group founder and CEO, Nasser Watar, only to face what Trophy Group alleges is retaliatory sabotage by Nissan. Trophy Group is represented by Amnon Siegel and Bryan Redfern of Miller Barondess, LLP.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327109484/en/

A Legacy of Success and Partnership

Since Trophy Group’s founding more than ten years ago, Nasser Watar, a veteran of the automotive industry, expanded Trophy Group to operate numerous successful dealerships in Southern California, including leading brands such as Mercedes-Benz and Kia. Its dealerships rank among the top-selling in the nation for their respective brands.

In addition to his U.S. operations, Watar has played a significant role in Nissan’s international distribution, particularly in the Middle East. From 2008 to 2019, he served as Vice Chairman, President and CEO of Nissan Gulf Company, a joint venture between Nissan Motor Co., Ltd. (“Nissan Japan”) and Al-Dahana Group. During Al-Dahana’s joint venture with Nissan Japan, Watar was CEO of Al-Dahana, as well as Nissan Gulf. Under Watar’s leadership, Nissan Gulf significantly expanded Nissan’s market presence, becoming the second-largest market leader in the Middle East and the most profitable Nissan subsidiary worldwide.

Nissan’s Initial Plea for Help

In 2017, recognizing Watar’s expertise, Nissan approached him to take over two struggling Los Angeles County dealerships—Universal City Nissan and West Covina Nissan. These once-successful dealerships had fallen into financial distress under their previous owner, Sage Automotive Group. Nissan sought Watar’s leadership to restore them to profitability, and Trophy Group acquired the dealerships. Initially, the transition was positive. With Nissan’s support, Watar and his team worked diligently to rebuild the dealerships’ reputation and performance.

Retaliation Following the Ghosn Scandal

In 2018, the arrest of former Nissan Japan CEO Carlos Ghosn sparked global controversy. As details emerged, Nissan Japan sought to sever ties with individuals and entities linked to the scandal—including Watar’s former business partner at Al-Dahana. Despite no allegations against Watar himself, Nissan unilaterally terminated its Gulf distribution partnership, prompting Al-Dahana to file suit. In 2021, Al-Dahana secured a $354 million judgment against Nissan Japan in Dubai.

In response, Nissan allegedly undertook a secret retaliatory campaign against Watar and Trophy Group’s U.S. dealerships, aiming to drive them out of business. Per the complaint, Nissan systematically under-allocated vehicles to Universal City Nissan and West Covina Nissan, depriving them of essential inventory while favoring nearby competitors.

The Impact of Nissan’s Unlawful Actions

New vehicle allocation is the lifeblood of any dealership, and Nissan’s alleged actions created a devastating cycle: reduced inventory led to lower sales, which in turn resulted in further reduced allocations. Despite Watar’s repeated pleas for fair treatment, Nissan allegedly refused to provide the necessary inventory, deliberately crippling the Trophy Group’s Nissan dealerships and eventually forcing them to close their doors.

Nissan’s alleged actions have resulted in millions in damages to Trophy Group and have also deprived consumers of competitive options in the Los Angeles market. Trophy Group is pursuing all available legal remedies against Nissan for its alleged targeted campaign of economic destruction.

“Nissan’s conduct represents an abuse of power and a blatant disregard for proper and fair business practices,” said Amnon Siegel. “We will not allow Nissan to unlawfully eliminate a trusted and dedicated dealer through manipulation and bad faith and look forward to the opportunity to present our case to a jury.”

The case is Trophy Universal City Group, LLC, et al. v. Nissan North America, Inc., et al., Los Angeles County Superior Court, Case No. [pending]

About Miller Barondess, LLP:

Miller Barondess, LLP is a Los Angeles-based law firm that specializes in litigation, including trial, arbitration, and appellate proceedings in California and nationwide. The firm represents both plaintiffs and defendants across a wide range of sectors, including automotive, consumer products, private equity, securities, financial services, intellectual property, patents, licensing and branding, technology and cybersecurity, real estate, healthcare, entertainment and music, sports, insurance, retail, environmental, and government. With a reputation for winning bet-the-company litigation, the firm is frequently engaged to resolve pivotal issues before trial, and other law firms bring in Miller Barondess when their clients need a trial or appellate team.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250327109484/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye